Related Experiment Video

Updated: Dec 28, 2025

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K

Differential effects of RhoA signaling on anticancer agent-induced cell death

Won Ki Kang1, Inkyoung Lee, Ukyoung Ko

  • 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 Seoul, Korea. wkkang@smc.samsung.co.kr

Oncology Reports
|January 12, 2005
PubMed

Insights

RhoA signaling differentially affects cancer cell death, conferring resistance to some anticancer drugs like statin and etoposide, while increasing sensitivity to others like vincristine. This modulation of apoptosis impacts cancer treatment strategies.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • RhoA signaling is established in cell adhesion and cytoskeletal dynamics.
  • Its role in cancer cell survival and apoptosis is less understood.
  • Anticancer agents induce apoptosis, a key target for drug resistance.

Purpose of the Study:

  • To investigate the role of RhoA in modulating cancer cell apoptosis induced by various anticancer agents.
  • To determine if RhoA influences sensitivity or resistance to specific chemotherapy drugs.

Main Methods:

  • Utilized constitutively active RhoA (caRhoA) transfectants and mock-transfected controls.
  • Assessed cell viability and apoptosis using IC50 values against statin, etoposide, 5-FU, taxol, and vincristine.
  • Performed Western blot analysis for cell cycle regulators (E2F-1, Cdk2, PCNA, p21, p27).
  • Conducted cleavage assays for apoptosis markers (PARP, BID, caspase-3, caspase-8).

Main Results:

  • caRhoA expression significantly increased resistance to statin, etoposide, 5-FU, and taxol (2.6- to 3.5-fold).
  • caRhoA significantly increased sensitivity to vincristine.
  • RhoA modulated E2F-1, Cdk2, PCNA, p21, and p27 expression.
  • Apoptosis inhibition was confirmed via cleavage assays, indicating RhoA's anti-apoptotic role in response to certain agents.

Conclusions:

  • RhoA acts as a differential modulator of apoptosis in cancer cells treated with anticancer agents.
  • RhoA confers resistance to several common chemotherapeutics but enhances sensitivity to vincristine.
  • RhoA's influence on cell death pathways is context-dependent on the specific anticancer agent used.

More Related Videos

RhoC GTPase Activation Assay09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

12.9K
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

13.8K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
Cell Polarization by Rho Proteins01:21

Cell Polarization by Rho Proteins

Cell polarity is the asymmetric distribution of cellular and membrane components, making one side of the cell different from the other. This polarity is essential to many processes such as embryogenesis, axon migration, glucose transport across epithelial cells, and directional cell migration. A migrating cell responds to intracellular or extracellular signals via molecular cascades that reorganize the actin cytoskeleton to establish this polarity. In these cells, the Rho family proteins Cdc42,...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K